B-cell precursor (BCP) acute lymphoblastic leukemia (BCP-ALL) in infants (ie, children age <1 year) is a rare disease traditionally subdivided into MLL-rearranged (alias KMT2A; MLL-R) and MLL germ line (MLL-G) subtypes. MLL gene rearrangements occur in ∼75% of infants with BCP-ALL1-3 and are typically associated with a mixed-lineage phenotype.4 MLL rearrangements originate prenatally in utero5 and play a role in transcription factor dysregulation.6 MLL-R BCP-ALL in infants is associated with dismal outcomes.1-3 Infants with MLL-G ALL treated with intensive therapies in the Interfant-06 protocol may have a relatively favorable prognosis, with a 6-year event-free survival (EFS) rate of 73.9%,2 slightly inferior to that observed in older children with BCP-ALL.1,2 Of interest, a recent study from the Japanese Pediatric Leukemia/Lymphoma Study Group MLL-10 trial reported more favorable outcomes in infants

Fazio, G., Bardini, M., De Lorenzo, P., Grioni, A., Quadri, M., Pedace, L., et al. (2021). Recurrent genetic fusions redefine MLL germ line acute lymphoblastic leukemia in infants. BLOOD, 137(14), 1980-1984 [10.1182/blood.2020009032].

Recurrent genetic fusions redefine MLL germ line acute lymphoblastic leukemia in infants

Fazio G.;Bardini M.;Grioni A.;Quadri M.;Palmi C.;Conter V.;Rizzari C.;Valsecchi M. G.;Biondi A.;Cazzaniga G.
2021

Abstract

B-cell precursor (BCP) acute lymphoblastic leukemia (BCP-ALL) in infants (ie, children age <1 year) is a rare disease traditionally subdivided into MLL-rearranged (alias KMT2A; MLL-R) and MLL germ line (MLL-G) subtypes. MLL gene rearrangements occur in ∼75% of infants with BCP-ALL1-3 and are typically associated with a mixed-lineage phenotype.4 MLL rearrangements originate prenatally in utero5 and play a role in transcription factor dysregulation.6 MLL-R BCP-ALL in infants is associated with dismal outcomes.1-3 Infants with MLL-G ALL treated with intensive therapies in the Interfant-06 protocol may have a relatively favorable prognosis, with a 6-year event-free survival (EFS) rate of 73.9%,2 slightly inferior to that observed in older children with BCP-ALL.1,2 Of interest, a recent study from the Japanese Pediatric Leukemia/Lymphoma Study Group MLL-10 trial reported more favorable outcomes in infants
Lettera in rivista
Lymphoid Neoplasia, Pediatric Hematology
English
1980
1984
5
Fazio, G., Bardini, M., De Lorenzo, P., Grioni, A., Quadri, M., Pedace, L., et al. (2021). Recurrent genetic fusions redefine MLL germ line acute lymphoblastic leukemia in infants. BLOOD, 137(14), 1980-1984 [10.1182/blood.2020009032].
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/314716
Citazioni
  • Scopus 5
  • ???jsp.display-item.citation.isi??? 4
Social impact